Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection.
about
Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient.Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection.Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment StrategiesHost phosphatidic acid phosphatase lipin1 is rate limiting for functional hepatitis C virus replicase complex formation
P2860
Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection.
@en
Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection.
@nl
type
label
Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection.
@en
Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection.
@nl
prefLabel
Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection.
@en
Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection.
@nl
P2860
P1476
Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection.
@en
P2093
Aliaksandr Budovich
P2860
P304
P577
2014-05-01T00:00:00Z